Effect of CYP2C19 genotype on control of gastric acidity with rabeprazole and esomeprazole after single and repeated oral administration

William P. Geus; Nicole G. Hunfeld; Daan J. Touw; Jesse T. Sarneel; Paul G. Mulder

doi:10.1016/S0016-5085(09)62284-8

Effect of CYP2C19 genotype on control of gastric acidity with rabeprazole and esomeprazole after single and repeated oral administration

William P. Geus
, Nicole G. Hunfeld
, Daan J. Touw
, Jesse T. Sarneel
, Paul G. Mulder

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Introduction: Esomeprazole (eso) and rabeprazole (rabe) are metabolized in the liver. Genetic polymorphism of the cytochrome P-450 enzyme CYP2C19 determines fast (homozygous extensive metabolizers, wt/wt), intermediate (heterozygous extensive metabolizers, wt/∗2 or wt/∗3) and slow (poor metabolizers, ∗2/∗2, ∗3/∗3 or ∗2/∗3) or rapid (wt/∗17 or ∗17/∗17) metabolism of proton pump inhibitors (PPIs). In the Caucasian population 60% has the wt/ wt genotype, 30-40% is wt/∗2 and 2-5% ∗2/∗2. Aim: To investigate the impact of CYP2C19 genotype on control of gastric acidity (median pH and % of time pH

Original language	English
Pages (from-to)	496
Number of pages	1
Journal	Gastroenterology
Volume	136
Issue number	5
DOIs	https://doi.org/10.1016/S0016-5085(09)62284-8
Publication status	Published - 1-May-2009

Keywords

esomeprazole
rabeprazole
cytochrome P450
enzyme
genomic DNA
acid
proton pump inhibitor
DNA
oral drug administration
genotype
stomach pH
gastrointestinal disease
pH
Caucasian
genetic polymorphism
metabolism
population
pylorus
normal human
analysis of variance
crossover procedure
gastric pH monitoring
model
male
stomach acid
liver

Access to Document

10.1016/S0016-5085(09)62284-8

Handle.net

Persistent link

Embargoed Document

Effect of CYP2C19 genotype on control of gastric acidity with rabeprazole
Final publisher's version, 127 KB
Request copy

Cite this

@article{4571ca649f714499aee0b8a5e0cdac2a,

title = "Effect of CYP2C19 genotype on control of gastric acidity with rabeprazole and esomeprazole after single and repeated oral administration",

abstract = "Introduction: Esomeprazole (eso) and rabeprazole (rabe) are metabolized in the liver. Genetic polymorphism of the cytochrome P-450 enzyme CYP2C19 determines fast (homozygous extensive metabolizers, wt/wt), intermediate (heterozygous extensive metabolizers, wt/∗2 or wt/∗3) and slow (poor metabolizers, ∗2/∗2, ∗3/∗3 or ∗2/∗3) or rapid (wt/∗17 or ∗17/∗17) metabolism of proton pump inhibitors (PPIs). In the Caucasian population 60\% has the wt/ wt genotype, 30-40\% is wt/∗2 and 2-5\% ∗2/∗2. Aim: To investigate the impact of CYP2C19 genotype on control of gastric acidity (median pH and \% of time pH",

keywords = "esomeprazole, rabeprazole, cytochrome P450, enzyme, genomic DNA, acid, proton pump inhibitor, DNA, oral drug administration, genotype, stomach pH, gastrointestinal disease, pH, Caucasian, genetic polymorphism, metabolism, population, pylorus, normal human, analysis of variance, crossover procedure, gastric pH monitoring, model, male, stomach acid, liver",

author = "Geus, \{William P.\} and Hunfeld, \{Nicole G.\} and Touw, \{Daan J.\} and Sarneel, \{Jesse T.\} and Mulder, \{Paul G.\}",

year = "2009",

month = may,

day = "1",

doi = "10.1016/S0016-5085(09)62284-8",

language = "English",

volume = "136",

pages = "496",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W B SAUNDERS CO-ELSEVIER INC",

number = "5",

}

TY - JOUR

T1 - Effect of CYP2C19 genotype on control of gastric acidity with rabeprazole and esomeprazole after single and repeated oral administration

AU - Geus, William P.

AU - Hunfeld, Nicole G.

AU - Touw, Daan J.

AU - Sarneel, Jesse T.

AU - Mulder, Paul G.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Introduction: Esomeprazole (eso) and rabeprazole (rabe) are metabolized in the liver. Genetic polymorphism of the cytochrome P-450 enzyme CYP2C19 determines fast (homozygous extensive metabolizers, wt/wt), intermediate (heterozygous extensive metabolizers, wt/∗2 or wt/∗3) and slow (poor metabolizers, ∗2/∗2, ∗3/∗3 or ∗2/∗3) or rapid (wt/∗17 or ∗17/∗17) metabolism of proton pump inhibitors (PPIs). In the Caucasian population 60% has the wt/ wt genotype, 30-40% is wt/∗2 and 2-5% ∗2/∗2. Aim: To investigate the impact of CYP2C19 genotype on control of gastric acidity (median pH and % of time pH

AB - Introduction: Esomeprazole (eso) and rabeprazole (rabe) are metabolized in the liver. Genetic polymorphism of the cytochrome P-450 enzyme CYP2C19 determines fast (homozygous extensive metabolizers, wt/wt), intermediate (heterozygous extensive metabolizers, wt/∗2 or wt/∗3) and slow (poor metabolizers, ∗2/∗2, ∗3/∗3 or ∗2/∗3) or rapid (wt/∗17 or ∗17/∗17) metabolism of proton pump inhibitors (PPIs). In the Caucasian population 60% has the wt/ wt genotype, 30-40% is wt/∗2 and 2-5% ∗2/∗2. Aim: To investigate the impact of CYP2C19 genotype on control of gastric acidity (median pH and % of time pH

KW - esomeprazole

KW - rabeprazole

KW - cytochrome P450

KW - enzyme

KW - genomic DNA

KW - acid

KW - proton pump inhibitor

KW - DNA

KW - oral drug administration

KW - genotype

KW - stomach pH

KW - gastrointestinal disease

KW - pH

KW - Caucasian

KW - genetic polymorphism

KW - metabolism

KW - population

KW - pylorus

KW - normal human

KW - analysis of variance

KW - crossover procedure

KW - gastric pH monitoring

KW - model

KW - male

KW - stomach acid

KW - liver

U2 - 10.1016/S0016-5085(09)62284-8

DO - 10.1016/S0016-5085(09)62284-8

M3 - Article

SN - 0016-5085

VL - 136

SP - 496

JO - Gastroenterology

JF - Gastroenterology

IS - 5

ER -

Effect of CYP2C19 genotype on control of gastric acidity with rabeprazole and esomeprazole after single and repeated oral administration

Abstract

Keywords

Access to Document

Handle.net

Embargoed Document

Fingerprint

Cite this